Skip to content
drillr.ai

LH

Labcorp Holdings Inc.

NYSE · USHealthcareMedical - Equipment & Services
$281.48-0.66%

Price as of Jul 20, 2026

LH news

Labcorp Holdings Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Labcorp Declares Quarterly Dividend

    Labcorp Declares Quarterly Dividend PR Newswire BURLINGTON, N.C., July 9, 2026 BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4728981-1&h=2748063213&u=http%3A%2F%2Fwww.labcorp.com%2F&a=Labcorp+Holdings+Inc.) (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable

    PR Newswire ·

  2. Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026

    Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026 PR Newswire BURLINGTON, N.C., June 30, 2026 BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4722904-1&h=3009139579&u=https%3A%2F%2Fwww.labcorp.com%2F&a=Labcorp+Holdings+Inc) . (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thu

    PR Newswire ·

  3. Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

    Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test PR Newswire BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 * First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas * Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling * Meets screening gu

    PR Newswire ·

  4. Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

    Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire BURLINGTON, N.C., May 29, 2026 Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4

    PR Newswire ·

  5. Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

    Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects PR Newswire BURLINGTON, N.C., May 28, 2026 New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4698279-1&h=2088259655&u=http%3A%2F%2Fwww.labcorp.com%2F&a=Labcorp) (NYSE: LH), a

    PR Newswire ·

  6. Labcorp to Present at the Jefferies Global Healthcare Conference

    Labcorp to Present at the Jefferies Global Healthcare Conference PR Newswire BURLINGTON, N.C., May 27, 2026 BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4696617-1&h=3390169527&u=http%3A%2F%2Fwww.labcorp.com%2F&a=Labcorp) (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 1

    PR Newswire ·

  7. Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis

    Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis New Foundation Trustees and Company Board Appointed to Oversee Knoa Pharma’s Public Health Purpose; Company Board to Ensure Safe and Responsible Operations Knoa Pharma LLC (“Knoa Pharma”) today begins operations as an independent company created to ensure safe access to medicines that are critical to patient care and to support communities with a purpose dedicate

    Business Wire ·

  8. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

    Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance PR Newswire BURLINGTON, N.C., April 30, 2026 * Results from Operations for first quarter 2026 versus first quarter 2025: * Revenue: $3.54 billion vs. $3.35 billion, up 5.8% * Diluted EPS: $3.35 vs. $2.52, up 32.8% * Adjusted EPS: $4.25 vs. $3.84, up 10.6% * Raised Full-Year Enterprise Revenue and Adjusted EPS guidance: * Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint * Adjusted EPS range of

    PR Newswire ·

  9. Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes

    Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes PR Newswire BURLINGTON, N.C., April 15, 2026 * First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second counts * Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics BURLINGTON, N.C., April 15, 2026 /PRNewswire/ -- Labcorp (https://edge.prnewswire.com/c/li

    PR Newswire ·

  10. Labcorp to Announce First Quarter Financial Results on April 30, 2026

    Labcorp to Announce First Quarter Financial Results on April 30, 2026 PR Newswire BURLINGTON, N.C., March 31, 2026 BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4654030-1&h=1042460124&u=https%3A%2F%2Fwww.labcorp.com%2F&a=Labcorp+Holdings+Inc) . (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday,

    PR Newswire ·

  11. Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

    Illumina and Labcorp expand collaboration to broaden access to precision oncology testing PR Newswire SAN DIEGO, March 18, 2026 SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to

    PR Newswire ·